| Species |
Human |
| Protein Construction |
CD7 (Ala26-Pro180)
Accession # P09564 |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD7 [Biotin], His & Avi, Human at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5 μg/ml) can bind Anti-CD7 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
19.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 34-48 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS，(pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD7, also known as Leu-9, is an approximately 40 kDa glycosylated and palmitoylated transmembrane protein in the immunoglobulin superfamily.CD7 is expressed on T cells, NK cells , myeloid progenitor cells, and CD19 B progenitor cells. Among CD8 T cells, the CD7-bright population preferentially contains naïve and memory cells, while more weak expressors are primarily effector cells. |
| Synonyms |
CD7 molecule; CD7; LEU-9; Tp40; TP41; GP40 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
